Bicycle Therapeutics is pioneering a new class of therapeutics to treat cancer and other debilitating diseases based on its proprietary bicyclic peptides (Bicycles®) platform. Bicycles® are a breakthrough new therapeutic class that combine antibody-like affinity and selectivity with small molecule-like tissue penetration, tuneable exposure and chemical synthesis. Bicycle Therapeutics is rapidly advancing towards the clinic with its lead programs using Bicycle Drug Conjugates® to selectively deliver toxins to tumours. Bicycle Therapeutics is collaborating in oncology and other areas to realise the full potential of the technology.

Bicycle Therapeutics’ unique intellectual property is based on the work initiated at the Medical Research Council Laboratory of Molecular Biology in Cambridge, U.K., by the scientific founders of the company: Sir Greg Winter, a pioneer in monoclonal antibody development, and Professor Christian Heinis, an accomplished researcher in the field of peptide therapeutics. This technology allows on phage presentation, cyclisation and screening of enormously diverse (>1012 variants), structurally constrained, peptidic libraries (Bicycles®). Bicycle Therapeutics is headquartered in Cambridge, U.K. and has U.S. operations in Cambridge, Massachusetts.

Bicycle Therapeutics is backed by a top-tier investor syndicate and closed a $32 million Series A funding round in October 2014.